Rob Lambkin-Williams

发表

J. Oxford, Rob Lambkin-Williams, A. Mann, 1968, Leaving The Arena.

Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans.

L. Carin, Rob Lambkin-Williams, A. Hero, 2009, Cell host & microbe.

A Host Transcriptional Signature for Presymptomatic Detection of Infection in Humans Exposed to Influenza H1N1 or H3N2

L. Carin, Rob Lambkin-Williams, A. Hero, 2013, PloS one.

A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2011, Vaccine.

Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2010, Vaccine.

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

Rob Lambkin-Williams, E. Walsh, J. Gollob, 2010, Proceedings of the National Academy of Sciences.

Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

J. Oxford, Rob Lambkin-Williams, A. Mann, 2010, American journal of respiratory and critical care medicine.

Oral GS-5806 activity in a respiratory syncytial virus challenge study.

Rob Lambkin-Williams, S. Lewis, R. Jordan, 2014, The New England journal of medicine.

Flu: Effect of Vaccine in Elderly Care Home Residents: A Randomized Trial

J. Oxford, Rob Lambkin-Williams, F. Gaughran, 2007, Journal of the American Geriatrics Society.

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial.

J. Oxford, Rob Lambkin-Williams, M. Zambon, 2009, Vaccine.

Risk Factors Associated with Severe Clinical Outcomes of Pandemic H1N1 Infection

Daniel J. Fullen, Rob Lambkin-Williams, 2014 .

A COVID‐19 human viral challenge model. Learning from experience

Rob Lambkin-Williams, J. Devincenzo, 2020, Influenza and other respiratory viruses.

Nasopharyngeal Protein Biomarkers of Acute Respiratory Virus Infection

Ricardo Henao, Rob Lambkin-Williams, A. Hero, 2017, EBioMedicine.

Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model.

J. Oxford, Rob Lambkin-Williams, A. Gilbert, 2014, The Journal of infectious diseases.

A COVID‐19 human viral challenge model. Learning from experience

Rob Lambkin-Williams, J. Devincenzo, J. DeVincenzo, 2020, Influenza and other respiratory viruses.

Reply to Hunsberger and Memoli, “Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat”

Rob Lambkin-Williams, Haiyin Chen-Harris, C. Rosenberger, 2017, Antimicrobial Agents and Chemotherapy.

A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

Rob Lambkin-Williams, A. Gilbert, H. Schuitemaker, 2021, The Journal of infectious diseases.

Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge

J. Oxford, Rob Lambkin-Williams, A. Mann, 2014, PloS one.

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

J. Oxford, Rob Lambkin-Williams, A. Gilbert, 2012, Nature Medicine.

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection

J. Oxford, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections.

Rob Lambkin-Williams, A. Zaas, C. Woods, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment

Rob Lambkin-Williams, A. Mann, S. Cauchemez, 2019, PLoS pathogens.

Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM).

Rob Lambkin-Williams, C. Laxton, N. Noulin, 2015, Journal of virological methods.

Minimal Transmission in an Influenza A (H3N2) Human Challenge-Transmission Model with Exposure Events in a Controlled Environment

Paul Jacob, Bueno de Mesquita, Rob Lambkin-Williams, 2019, SSRN Electronic Journal.

Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2020, Influenza and other respiratory viruses.

Influenza Vaccines Have a Short but Illustrious History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine in the Current Pandemic

J. Oxford, Rob Lambkin-Williams, A. Gilbert, 2010, Influenza Vaccines for the Future.

Influenza vaccines have a short but illustrious history

J. Oxford, Rob Lambkin-Williams, A. Gilbert, 2008, Influenza Vaccines for the Future.

Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification

Timothy B. Stockwell, Gavin J. D. Smith, Rob Lambkin-Williams, 2016, Journal of Virology.

The Effect of Influenza Virus on the Human Oropharyngeal Microbiome

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Animal models in influenza vaccine testing

J. Oxford, Rob Lambkin-Williams, A. Mann, 2008, Expert review of vaccines.

The effective rate of influenza reassortment is limited during human infection

Christopher J. R. Illingworth, Timothy B. Stockwell, Gavin J. D. Smith, 2017, PLoS pathogens.

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Re-Inventing the Common Cold Institute for the 21st Century

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2016 .

A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans

J. Oxford, Rob Lambkin-Williams, A. Mann, 2015, Clinical and Vaccine Immunology.

Running Title: Live virus challenge trial of T cell influenza vaccine 4

J. Oxford, Rob Lambkin-Williams, A. Mann, 2015 .

The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2018, Respiratory Research.

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

Rob Lambkin-Williams, Qingling Zhang, J. Symons, 2015, The New England journal of medicine.

Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model

Rob Lambkin-Williams, Haiyin Chen-Harris, C. Rosenberger, 2017, Antimicrobial Agents and Chemotherapy.

Inhibition of viral and bacterial trigger-stimulated prostaglandin E2 by a throat lozenge containing flurbiprofen: An in vitro study using a human respiratory epithelial cell line

Rob Lambkin-Williams, A. Mann, A. Shephard, 2020, SAGE open medicine.

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2018, BMC Research Notes.

Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study.

J. Oxford, Rob Lambkin-Williams, A. Gilbert, 2011, The Journal of infectious diseases.

Correlation between Human Leukocyte Antigen Class II Alleles and HAI Titers Detected Post-Influenza Vaccination

J. Oxford, Rob Lambkin-Williams, A. Mann, 2013, PloS one.

Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge

Ricardo Henao, Rob Lambkin-Williams, A. Mann, 2016, Clinical and experimental immunology.

A Genomic Signature of Influenza Infection Shows Potential for Presymptomatic Detection, Guiding Early Therapy, and Monitoring Clinical Responses

Rob Lambkin-Williams, A. Hero, A. Zaas, 2016, Open forum infectious diseases.

Comparing Influenza and Rsv Viral and Disease Dynamics in Experimentally Infected Adults Predicts Clinical Effectiveness of Rsv Antivirals

J. Oxford, Rob Lambkin-Williams, A. Mann, 2013, Antiviral therapy.

Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection

J. Oxford, Rob Lambkin-Williams, P. Rennie, 2007, Respiratory research.

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Andrew P. Catchpole, Daniel J. Fullen, Nicolas Noulin, 2018, BMC Research Notes.

Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2010, Vaccine.

A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.

Rob Lambkin-Williams, A. Mann, Y. Barenholz, 2011, Vaccine.

The Threat of Avian Influenza H5N1: ‘Do We Have the Tools for the Job?’

J. Oxford, Rob Lambkin-Williams, A. Mann, 2007, Antiviral chemistry & chemotherapy.

LB-1Treatment with Oral ALS-008176, a Nucleoside Analog, Rapidly Reduces RSV Viral Load and Clinical Disease Severity in a Healthy Volunteer Challenge Study

Rob Lambkin-Williams, Qingling Zhang, J. Symons, 2014 .

RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus

Rob Lambkin-Williams, A. Mann, A. Gilbert, 2013 .